Key result
Pharmacist-managed warfarin resulted in a similar median percentage of time in therapeutic range compared to cardiologist-managed care in pediatric patients (55.5% vs 54%, p=0.93).
Why the study?
Does pharmacist-managed warfarin improve time in therapeutic range compared to cardiologist-managed warfarin in pediatric cardiac patients?
Cohort (n=14)
Does pharmacist-managed warfarin improve time in therapeutic range compared to cardiologist-managed warfarin in pediatric cardiac patients?
Pharmacist-managed warfarin provides similar time in therapeutic range compared to cardiologist-managed care in pediatric cardiac patients, supporting its safety and efficacy in the outpatient setting.
Answers are grounded in this paper and cite their sources.
Pharmacist-managed warfarin yielded similar TTR in this tiny pediatric cohort; leaves open whether it extends safely to broader practice.
Objective: To compare the efficacy of warfarin management by a pharmacist-managed group to a cardiologist-managed group (usual care) in an outpatient pediatric population. Methods: Fourteen patients with an international normalized ratio (INR) goal determined by a cardiologist were included. The pharmacist-managed group included twelve patients. There were seven patients in the cardiologist-managed group. Prior to the transition to a pharmacist-managed service in September 2014, cardiologists managed anticoagulation. For the cardiologist-managed group, INR values were recorded for six months. Following a washout period of three months, INR values were obtained for the pharmacist-managed group for the subsequent six months. Patients were included in each analysis if they were followed for more than 3 months. A protocol guided dose adjustments, recommended monitoring, and allowed for pharmacist-managed warfarin. Results: The median number of INR tests per patient was not significantly lower in the cardiologist-managed group compared to the pharmacist-managed group (28 versus 36 measurements, p=0.06). The median percentage of time in therapeutic range using the Rosendaal method was not significantly higher in the pharmacist-managed group compared to the cardiologist-managed group (55.5% versus 54%, p=0.93). The median percentage of values in therapeutic range using the traditional method was also not significantly higher in the pharmacist-managed group compared to the cardiologist-managed group (41.9% versus 36.8%, p=0.93). Conclusion: Warfarin management in a pharmacist-managed group compared to a cardiologist-managed group provided similar care. Differences in time in therapeutic range and median values in therapeutic range were not found between the pharmacist-managed group and cardiologist-managed group. These results describe and provide support that pharmacist-managed anticoagulation of pediatric cardiology patients is safe and effective in the outpatient setting.
No takes yet. Share an insight, caveat, or question.
Tilton et al. (2018) conducted a cohort in Pediatric cardiac patients requiring anticoagulation (n=14). Pharmacist-managed warfarin vs. Cardiologist-managed warfarin (usual care) was evaluated on Median percentage of time in therapeutic range using the Rosendaal method (p=0.93). Pharmacist-managed warfarin resulted in a similar median percentage of time in therapeutic range compared to cardiologist-managed care in pediatric patients (55.5% vs 54%, p=0.93).
Synapse has enriched 10 related papers. Consider them for comparative context: